Centogene NV

As of February 10, 2020, Centogene NV is considered risky and overvalued due to severe financial distress, reflected in its negative price-to-book value, negative EV to EBITDA ratio, alarming return on capital employed, and significant underperformance compared to the S&P 500.

As of June 17, 2025, Centogene NV shows a mildly bullish trend supported by daily moving averages and MACD, but mixed signals from weekly KST and Dow Theory indicate caution.

As of March 2022, the management team of Centogene NV includes Dr. Flemming Ornskov (Chairman), Mr. Peer Schatz (Independent Vice Chairman), and several independent members: Dr. Hubert Birner, Mr. Berndt Modig, Mr. Guido Prehn, Dr. Eric Souetre, and Mr. Christoph Ehlers. They are responsible for the company's strategic direction and governance.

Centogene NV is a Germany-based company specializing in rare diseases, converting clinical, genetic, and biochemical data into medical solutions. As of June 2022, it reported net sales of $12 million and a net loss of $13 million, with a market cap of $4.27 million.

As of Jun 18, Centogene NV has a market capitalization of 4.27 million, categorizing it as a Micro Cap company. As of Jun 22, it reported net sales of 108.13 million but a net profit of -64.65 million, with shareholder's funds of -27.93 million and total assets of 85.23 million as of Dec 23.